Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
Clinical trial NCT03722420 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03722420
- Sponsor
- Il-Yang Pharm. Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-28
- Primary completion
- 2023-03-03
- Enrollment
- 238
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.